Status:
COMPLETED
Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease
Lead Sponsor:
Bayer
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18+ years
Brief Summary
The use of acarbose in impaired glucose tolerance (IGT) and type 2 diabetic subjects has been associated with a significant reduction of cardiovascular events. Additionally, acarbose has been shown to...
Eligibility Criteria
Inclusion
- Diabetes Mellitus
- Age \>/= 18 years
- Naive to acarbose (minimum 3 months before inclusion)
Exclusion
- Hypersensitivity to acarbose or any of the excipients
- Age \<18 years
- Pregnancy and in nursing
- Inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction
- Chronic intestinal diseases associated with marked disorders of digestion or absorption
- States which may deteriorate as a result of increased gas formation in the intestine, (e.g. Roemheld's syndrome \[an angina pectoris-like syndrome or aggravation of an angina pectoris due to the postprandial filling of the stomach\] and larger hernias)
- Hepatic and severe renal impairment (creatinine clearance \<25 mL/min/ 1,73m2)
Key Trial Info
Start Date :
May 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
3310 Patients enrolled
Trial Details
Trial ID
NCT01167231
Start Date
May 1 2007
End Date
June 1 2008
Last Update
August 25 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Poland